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At a glance summary: 1 
Scientific Knowledge on the Subject: The exact mechanisms used by alveolar 2 
macrophages (AM) to kill extracellular bacteria remain unclear. 3 
What This Study Adds to the Field: We have generated a novel transgenic mouse with 4 
AM which over-expresses the anti-apoptotic factor Mcl-1, a molecule that is over-5 
expressed in several patient groups at increased risk of pneumonia, which demonstrates 6 
this transgenic has a reduced capacity to clear bacteria from the lung. Apoptosis-7 
associated killing is activated when initial phagolysosomal mechanisms are exhausted 8 
and requires a combination of reactive species, including nitric oxide and mitochondrial-9 
derived reactive oxygen species. Re-engaging apoptosis when deficient 10 
pharmacologically helps prevent pneumonia in these murine models. 11 
 12 
This article has an online data supplement, which is accessible from this issue's table of 13 
content online at www.atsjournals.org 14 
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Abstract  1 
 2 
Rationale: Antimicrobial resistance challenges therapy of pneumonia. Enhancing 3 
macrophage microbicidal responses would combat this problem but is limited by our 4 
understanding of how alveolar macrophages (AM) kill bacteria.  5 
Objectives:  To define the role and mechanism of AM apoptosis-associated bacterial 6 
killing in the lung. 7 
Methods: We generated a unique CD68.hMcl-1 transgenic mouse with macrophage-8 
specific over-expression of the human anti-apoptotic Mcl-1 protein, a factor upregulated 9 
in AM from patients at increased risk of community-acquired pneumonia, to address the 10 
requirement for apoptosis-associated killing. 11 
Measurements and Main Results: Wild-type and transgenic macrophages 12 
demonstrated comparable ingestion and initial phagolysosomal killing of bacteria. 13 
Continued ingestion (for > 12 h) overwhelmed initial killing and a second late-phase 14 
microbicidal response killed viable bacteria in wild-type macrophages, but this response 15 
was blunted in CD68.hMcl-1 transgenic macrophages. The late-phase of bacterial killing 16 
required both caspase-induced generation of mitochondrial reactive oxygen species 17 
(mROS) and nitric oxide (NO), whose peak generation coincided with the late-phase of 18 
killing. The CD68.hMcl-1 transgene prevented mROS but not NO generation. 19 
Apoptosis-associated killing enhanced pulmonary clearance of Streptococcus 20 
pneumoniae and Haemophilus influenzae in wild-type but not CD68.hMcl-1 transgenic 21 
mice. Bacterial clearance was enhanced in vivo in CD68.hMcl-1 transgenic mice by 22 
reconstitution of apoptosis with BH3 mimetics or clodronate-encapsulated liposomes. 23 
Apoptosis-associated killing was not activated during Staphylococcus aureus lung 24 
infection.  25 
Conclusions: Mcl-1 upregulation prevents macrophage apoptosis-associated killing and 26 
establishes that apoptosis-associated killing is required to allow AM to clear ingested 27 
 4 
bacteria. Engagement of macrophage apoptosis should be investigated as a novel host-1 
based antimicrobial strategy. 2 
  3 
 5 
Introduction 1 
Community-acquired pneumonia (CAP), commonly caused by Streptococcus 2 
pneumoniae (the pneumococcus) and other bacteria, is a leading causes of global 3 
mortality (1). The plasticity of bacterial genomes challenges vaccination and facilitates 4 
antimicrobial resistance (2). Pathogenic bacteria frequently colonize the upper airway, 5 
but CAP is relatively uncommon, indicating efficient host responses protect most 6 
individuals.  7 
 8 
Tissue macrophages, such as alveolar macrophages (AM), are key effectors of 9 
antibacterial host defense (3), but the mechanisms used to kill extracellular bacteria after 10 
their internalization are incompletely defined. AM kill ingested bacteria in 11 
phagolysosomes, but this mechanism is less efficient than in other phagocytes. Tissue 12 
macrophages usually do not express myeloperoxidase (4) or the microbicidal serine 13 
proteases seen in neutrophils (5) and are less reliant on nicotinamide adenine 14 
dinucleotide phosphate (NADPH) oxidase-dependent reactive oxygen species (ROS) 15 
generation (6). Nitric oxide (NO) generation in human macrophages is also less vigorous 16 
than in rodent cells or monocytes (7, 8). Moreover, pneumococci and other bacterial 17 
pathogens frequently express genes that inhibit phagolysosomal killing (9).  Prolonged 18 
intracellular killing of bacteria is associated with macrophage apoptosis in human 19 
macrophages and in murine pneumonia models (3, 10). Although inhibition of apoptosis 20 
reduces bacterial killing in these murine models it has not been demonstrated if cell-21 
autonomous macrophage apoptosis mediates pathogen clearance (3, 11). Recently we 22 
have found that a key regulator of macrophage apoptosis during bacterial killing, the 23 
anti-apoptotic protein Mcl-1 (11), is upregulated in AM from patients at increased risk 24 
of CAP due to chronic obstructive pulmonary disease (COPD) or HIV-1 infection, 25 
where it is associated with reduced AM apoptosis and bacterial killing ex vivo (12, 13). 26 
 6 
Re-engaging microbicidal responses downstream of apoptosis restored bacterial killing 1 
in COPD AM (12) but whether apoptosis reconstitution in the presence of over-2 
expression of Mcl-1 restores bacterial killing is unknown. 3 
 4 
To test if macrophage cell autonomous over-expression of the human Mcl-1 transgene, 5 
as observed in these patients at increased risk of CAP, mediates bacterial clearance we 6 
generated transgenic mice that specifically express CD68.hMcl-1 in macrophages, since 7 
the viability of these cells is closely linked to expression of this anti-apoptotic protein 8 
(11, 14). We used this novel transgenic line with controlled infections and interventions 9 
to define the role, microbicidal mechanism and potential for therapeutic re-engagement 10 
of macrophage apoptosis-associated bacterial killing. Our findings show that 11 
macrophage apoptosis represents a second late-phase of bacterial killing, which is 12 
activated after initial lysosome-mediated mechanisms are exhausted upon sustained 13 
bacterial uptake. Apoptosis-associated bacterial killing requires mitochondrial (mROS), 14 
which act in combination with NO. This microbicidal mechanism was inhibited in the 15 
presence of CD68.hMcl-1, but was restored by BH3 mimetics or bisphosphonates.  16 
  17 
 7 
Materials and Methods 1 
Generation of CD68.hMcl-1 transgenic mice: A 1.5kb fragment containing the cDNA 2 
sequence for human Mcl-1 (15) was cloned into a plasmid containing 2.9 kb of the 3 
CD68 promoter with the first intron enhancer IVS (16) (Figure  1A). Correct orientation 4 
and PCR mismatches were confirmed by sequencing. The transgene was isolated by 5 
restriction enzyme digestion and gel purification. The transgene was microinjected into 6 
C57Bl/6J oocytes (Washington University School of Medicine, St Louis, USA). 7 
Founders and their progeny were genotyped by PCR amplification of tail or ear biopsy 8 
DNA using the following primers: 5Õ-ACCATCTCCTCTCTGCCAAA-3Õ and 5Õ-9 
GGGCTTCCATCTCCTCAA-3Õ. Two CD68.hMcl-1 mice transgenic lines were 10 
established. Both lines showed germline transmission and equivalent functional results. 11 
Mcl-1 transgenic mice and non-transgenic littermates, from the same cages, were 12 
inoculated with bacteria and sample collected as described previously (3) and in the on-13 
line supplement. 14 
 15 
Bacteria: Details on the bacteria and culture conditions are provided on-line. 16 
 17 
Isolation and culture of macrophages and other leukocytes: Bone marrow-derived 18 
macrophages (BMDM), resident AM , peritoneal macrophages (PM), peripheral blood 19 
neutrophils, B-cells and T-cells were obtained from C57Bl/6J mice (17, 18).  Human 20 
monocyte-derived macrophages (MDM) from whole blood donated by healthy 21 
volunteers (10). Further details are available on-line.  22 
 23 
 8 
Flow Cytometry and confocal microscopy: Further details on flow cytometry and 1 
confocal microscopy experiments are available in the on-line supplement. 2 
 3 
Intracellular killing assay: Assessment of intracellular bacterial viability was carried out 4 
as previously described (19), and outlined in the on-line supplement.  5 
 6 
Reconstitution of Apoptosis: Apoptosis was reconstituted in vitro with clodronate-7 
encapsulated liposomes or the indicated BH3 mimetics and in vivo AM apoptosis was 8 
reconstituted in transgenic mice using clodronate containing liposomes or the indicated 9 
BH3 mimetics (further information in the on-line supplement), with instillation of 10 
bacteria at the same time to ensure induction of early-stage apoptosis but not 11 
macrophage depletion (20). 12 
 13 
Ethics: Animal experiments were conducted in accordance with the Home Office 14 
Animals (Scientific Procedures) Act of 1986, authorized under a UK Home Office 15 
License 40/3251 with approval of the Sheffield Ethical Review Committee. MDM were 16 
isolated from healthy volunteers with written informed consent and approval from the 17 
South Sheffield Regional Ethics Committee.  18 
 19 
Statistics: Results are recorded as mean and SEM.  Sample sizes were informed by 20 
standard errors obtained from similar assays in prior publications (10, 11). D'Agostino-21 
Pearson normality tests guided test selection.   Comparisons between two conditions 22 
were performed using a paired or unpaired t-test for parametric data, or a Mann-Whitney 23 
U test or Wilcoxon signed rank test for non-parametric data using Prism 6.0 software 24 
(GraphPad Inc.). Comparisons between three or more conditions were performed using a 25 
 9 
normal or repeated measures 1-way ANOVA with Bonferroni post-test for parametric 1 
data, or a Friedman test with DunnÕs multiple comparison post-test for non-parametric 2 
data. When two or more conditions were assessed in two experimental groups data was 3 
analysed by 2-way ANOVA with Bonferroni post-test. Significance was defined as P < 4 
0.05.  5 
6 
 10 
Results 1 
CD68.hMcl-1 transgenic mice demonstrate reduced macrophage apoptosis 2 
A CD68 promoter construct (21) ensured macrophage-specific human Mcl-1 (hMcl-1) 3 
expression, to generate a transgenic mouse with selective apoptosis resistance in 4 
macrophages (Figure 1A). Equivalent functional results were generated from both 5 
founder lines.  Macrophage-specific hMcl-1 expression was documented in AM and 6 
other macrophage lineages in CD68.hMcl-1 transgenic mice (Figure 1B-D), but not 7 
neutrophils or lymphocytes (Figure 1E). CD68.hMcl-1 transgenic mice lacked a gross 8 
developmental phenotype or loss of fertility and showed normal survival. CD68.hMcl-1 9 
mice had normal numbers of leukocyte subsets in blood and of macrophage in tissues, 10 
while splenic lymphoid tissue and lung parenchyma showed no histological 11 
abnormalities (Figure E1A-F). 12 
 13 
Importantly, the transgene reduced susceptibility to apoptosis in bone marrow-derived 14 
macrophages, (CD68.hMcl-1
+ 
BMDM), AM and peritoneal macrophages (Figure 1F-H 15 
and E1G).  In contrast, CD68.hMcl-1
+ 
BMDM demonstrated no decrease in binding or 16 
ingestion of latex beads or in the numbers of viable intracellular bacteria present after 4 17 
h exposure to S. pneumoniae (a marker of early ingestion and killing (10)) (Figure E1H-18 
I).  The generation of ROS and NO was also unaltered by the transgene at 4 h (Figure 19 
E1J-K).  Mcl-1 thus did not alter initial innate immune responses.  20 
 21 
Mcl-1 expression regulates apoptosis-associated killing when phagolysosomal bacterial 22 
killing is exhausted 23 
Exposure of macrophages to pneumococci for 16-20 h results in apoptosis without a loss 24 
of membrane integrity (22). Importantly, this was inhibited in the presence of the 25 
 11 
CD68.hMcl-1
 
transgene, which acted at the level of the mitochondrial execution of the 1 
program of apoptosis (Figure E2A-D). The transgene also increased survival of ingested 2 
bacteria (Figure 2A), although it had no effect on lysosomal acidification, lysosomal 3 
membrane permeabilization, or activation of the lysosomal protease cathepsin D, which 4 
occurs upstream of the mitochondrial apoptotic program following pneumococcal 5 
challenge (11, 14) (Figure E2E-G). To prove that reduction of macrophage apoptosis 6 
was the mechanism by which Mcl-1 inhibited bacterial killing, apoptosis was 7 
reconstituted with the BH3 mimetic ABT-737. Although ABT-737 cannot reverse the 8 
anti-apoptotic effect of Mcl-1 directly, it interacts with Bcl-2/Bcl-XL, displacing pro-9 
apoptotic Bcl-2 proteins to stimulate apoptosis (23). ABT-737 increased the number of 10 
cells with loss of inner mitochondrial transmembrane potential (Δψm) and nuclear 11 
fragmentation in CD68.hMcl-1
+ 
BMDM exposed to pneumococci (Figure E3A-B), and 12 
restored apoptosis-associated intracellular bacterial killing (Figure 2B), while additional 13 
BH3 mimetics also increased bacterial killing at 20 h, but not at 4 h (Figure E3C-D). 14 
 15 
To dissect the role of apoptosis-associated killing in host defense, BMDM were ÔpulsedÕ 16 
with bacteria and the kinetics of killing of internalized bacteria were measured following 17 
antimicrobial ÔchaseÕ to remove extracellular bacteria. The ÔchaseÕ does not itself alter 18 
internalized bacteria since the cell membrane remains intact at this early-stage of 19 
apoptosis (22) and ensures that changes in viable bacteria are the result of intracellular 20 
killing but not continued phagocytosis. We identified two phases of intracellular killing. 21 
An initial-phase, occurring immediately after bacterial ingestion (Figure 2C), was 22 
consistent with phagocytosis-associated phagolysosomal killing (24) and was similar in 23 
transgenic and non-transgenic BMDM. A late-phase of intracellular killing occurred at 24 
16-20 h in non-transgenic BMDM but was blunted in CD68.hMcl-1
+ 
BMDM. This late-25 
phase coincided with the onset of apoptosis (Figure 2D) but occurred prior to any 26 
 12 
reduction in macrophage cell numbers (Figure 2E). By varying the duration of the 1 
ÔpulseÕ we confirmed that the initial phase of bacterial killing was sustained for up to 12 2 
h and that, after it ceased, the late-phase of killing cleared viable internalized bacteria 3 
(Figure 2F). Overall, the CD68.hMcl-1 transgene inhibited the late-phase of bacterial 4 
killing without any impact on early ingestion or killing.   5 
 6 
We tested whether bacterial ingestion was compromised after >12 h of exposure to 7 
bacteria, as this would remove the stimulus for phagolysosomal killing. We investigated 8 
this using a second ÔpulseÕ with a distinct strain of bacteria (Figure 2G). Bacterial 9 
internalization occurred at >12 h in the presence or absence of the Mcl-1 transgene, but 10 
was accompanied by continued intracellular killing only in CD68.hMcl-1
-
 BMDM. 11 
Sustained bacterial ingestion activated a late-phase of killing, requiring apoptosis 12 
induction, killing viable internalized bacteria. 13 
 14 
Mitochondrial ROS is required for apoptosis-associated bacterial killing 15 
An inhibitor of nitric oxide synthase (NOS) 2 reduced both the late-phase of bacterial 16 
killing and apoptosis in non-transgenic BMDM (Figure 3A-B). This suggested that NO 17 
generation contributed to bacterial killing, but occurred upstream of apoptosis, 18 
consistent with its known role in sensitizing mitochondria to apoptosis induction (19). 19 
An antioxidant also inhibited late-phase bacterial killing, although it did not affect 20 
apoptosis-induction.  This suggested that ROS are also required for this phase, but are 21 
generated downstream or as a result of apoptosis. Since NADPH oxidase does not 22 
contribute to macrophage apoptosis-associated killing during pneumococcal infection 23 
(25), we addressed another source of antimicrobial ROS, mitochondrial ROS (mROS) 24 
(26). 25 
  26 
 13 
Increased mROS were apparent after 16-20 h of bacterial exposure, but were reduced by 1 
the Mcl-1 transgene (Figure 3C). Peak generation of mROS co-incided with peak NO 2 
production in human MDM (Figure E4A) and mROS/NO co-localized with bacteria 3 
(Figure E4-6). Since mROS generation was a late response contemporaneous with 4 
apoptosis onset we tested whether caspase 3 activation, which inhibits mitochondrial 5 
electron transport complex I and II, contributed to mROS generation (27). Caspase 6 
activation increased mROS production and, consistent with the role of Mcl-1 in limiting 7 
caspase activation, the caspase 3/7
+ 
population was expanded in non-transgenic versus 8 
transgenic
 
BMDM and produced significantly more mROS after 20 h of exposure to 9 
bacteria (Figure 3D). Comparable findings were observed in human MDM (Figure 3E). 10 
Crucially, an inhibitor of mROS, mitoTEMPO, blocked the late-phase of pneumococcal 11 
killing in CD68.hMcl-1
-
 (but not CD68.hMcl-1
+
) BMDM (Figure 3F) and also in human 12 
MDM (Figure 3G). Inhibition of mROS did not modify BMDM apoptosis-induction or 13 
Mcl-1 expression (Figure 3H and 3I), consistent with mROS acting downstream of 14 
apoptosis in bacterial killing. Since mROS also activates pro-inflammatory cytokine 15 
expression (28) we confirmed differential cytokine expression was not contributing to 16 
differences in late microbicidal responses (Figure E7 A-C). Since pneumococci 17 
intrinsically resist oxidative stress (29), our results suggest apoptosis-associated killing 18 
requires caspase-dependent mROS generation, combined with NO, to mediate bacterial 19 
killing  20 
 21 
Apoptosis-associated killing is required for bacterial clearance in vivo 22 
We next addressed the role of apoptosis-associated bacterial killing by AM in vivo. 23 
Initially we used a low-dose of pneumococci which AM clear efficiently, an 24 
intermediate dose, which represents the Ôtipping-pointÕ at which AM start to fail to 25 
control infection and where any increase in dose or perturbation of macrophage function 26 
 14 
results in development of pneumonia, and a high doses where AM are overwhelmed and 1 
mice develop systemic infection (3, 30). CD68.hMcl-1
+
 transgenic mice failed to clear 2 
the low dose of pneumococci (10
4 
colony forming units; CFU) by 24 h, while non-3 
transgenic mice cleared all bacteria (Figure 4A) (3). Only transgenic mice developed 4 
bacteremia at the low dose (Figure 4B). At intermediate doses, CD68.hMcl-1
+ 
transgenic 5 
mice also exhibited increased bacterial CFU in lungs and blood compared to non-6 
transgenic mice. Crucially the transgenic mice had significant neutrophil recruitment in 7 
BAL at this intermediate dose, a feature of pneumonia, while the non-transgenic animals 8 
had no neutrophil recruitment (Figure 4C).  AM numbers were not altered by low dose 9 
infection or transgene expression but were only reduced in the high dose infection in 10 
transgenic mice in association with high-levels of inflammatory cell recruitment (Figure 11 
4D). The bacterial clearance that occurred in non-transgenic animals was completely 12 
overwhelmed as expected at an inoculum of 10
7 
CFU macrophages (3). Along with 13 
reduced bacterial clearance and an increased requirement for neutrophil recruitment, 14 
CD68.hMcl-1
+ 
transgenic mice exhibited reduced AM apoptosis in bronchoalveolar 15 
lavage (BAL) following bacterial challenge (Figure 4E). To exclude any role for low 16 
numbers of lung neutrophils in the differential clearance of bacteria we repeated low 17 
dose bacterial challenge after neutrophil depletion and again confirmed reduced bacterial 18 
clearance in the transgenic mice (Figure E8). Overall this proved the transgene reduced 19 
bacterial replication and also the threshold at which neutrophils were recruited to control 20 
bacteria in the lung, but only during the specific stages where AM are the major effector 21 
of bacterial clearance in the lung.  22 
 23 
CD68.hMcl-1
+ 
transgenic mice also exhibited impaired clearance of low doses of H. 24 
influenzae, another respiratory pathogen (31). At high doses, infection progressed to 25 
pneumonia with pulmonary neutrophil recruitment in all mice, since AM clearance 26 
 15 
capacity was overwhelmed (Figure 4F-G). Reduced bacterial clearance at low doses was 1 
also associated with reduced macrophage apoptosis in the BAL (Figure 4H). Apoptosis-2 
associated killing likewise contributed to bacterial clearance at extra-pulmonary sites: 3 
CD68.hMcl-1
+ 
transgenic mice given a low peritoneal dose of S. pneumoniae showed 4 
impaired peritoneal clearance of bacteria, increased numbers of bacteria in blood, 5 
enhanced neutrophil numbers and reduced macrophage apoptosis (Figure 4I-L).  6 
 7 
Re-engagement of macrophage apoptosis enhances pulmonary bacterial clearance in 8 
vivo 9 
To confirm that the differential levels of apoptosis explained the transgene effect in vivo, 10 
we reconstituted AM apoptosis in the CD68.hMcl-1
+ 
transgenic mice using liposomes 11 
containing clodronate (20). Liposomes ensure macrophage targeting through phagocytic 12 
uptake, while clodronate induces a mitochondrial pathway of apoptosis with loss of Δψm 13 
providing an alternative route of engagement of the mitochondrial apoptosis pathway in 14 
the absence of Mcl-1 downregulation (32, 33). Liposome dosing was adjusted to induce 15 
apoptosis in CD68.hMcl-1
+ 
BMDM exposed to bacteria (Figure 5A), without altering 16 
bacterial internalization (Figure 5B). In vivo we administered liposomes at the same time 17 
as bacteria, to ensure that the early stages of liposome-induced AM apoptosis occurred 18 
together with the initiation of the anti-bacterial apoptotic program and before AM 19 
depletion reduced AM numbers (Figure 5C and 5D). Reconstitution of AM apoptosis in 20 
CD68.hMcl-1
+ 
AM increased bacterial clearance from the lung, reduced levels of 21 
bacteria in the blood, and reduced neutrophil numbers in BAL (Figure 5E-G). Similar 22 
results were obtained with BH3 mimetics (ABT-263, an oral derivative of ABT-737 and 23 
sabutoclax, a pan Bcl-2 family inhibitor (34)). These increased bacterial clearance from 24 
lung and blood (Figure 5H-I) and AM apoptosis but not AM numbers, in infections 25 
 16 
inducing minimal neutrophil recruitment (Figure E9). They also reduced viable bacteria 1 
in MDM at late, but not early time-points (Figure E9D-E). 2 
 3 
Adoptive transfer of bone marrow between non-transgenic and transgenic mice 4 
confirmed our results reflected macrophage expression of the transgene. Bone marrow 5 
transplantation reduces the ability of mice to clear the low dose of pneumococci (14, 35) 6 
and bacteria were not completely cleared in either group of mice (Figure E10A-B). 7 
However, the recipients of transgenic bone marrow exhibited reduced AM apoptosis and 8 
greater numbers of macrophage-associated bacteria (consistent with reduced 9 
intracellular clearance), while recruiting significantly more neutrophils (Figure E10C-E).  10 
This suggested that there was less effective macrophage killing in transgenic mice. 11 
 12 
Staphylococcus aureus infection does not activate apoptosis-associated killing 13 
Staphylococcus aureus upregulates Mcl-1 in macrophages (36). We wondered whether 14 
this would phenocopy the effects seen with the CD68.hMcl-1 transgene. Induction of 15 
macrophage apoptosis requires downregulation of Mcl-1 to allow mitochondrial outer 16 
membrane permeabilization (MOMP) and the execution phase of apoptosis (11, 14). S. 17 
aureus failed to induce the anticipated Mcl-1 downregulation after sustained bacterial 18 
ingestion (Figure E11A). Moreover, it was not associated with apoptosis or late-phase 19 
bacterial killing (Figure 6A-B), despite
 
exhaustion of
 
the initial phase of killing in the 20 
setting of sustained ingestion of bacteria (Figure 6C-D). Exposure in vivo to a range of 21 
bacterial doses (from doses AM can control to 100-fold higher) did not reveal any 22 
differences in bacterial clearance, neutrophil recruitment, or AM apoptosis irrespective 23 
of transgene expression (Figure 6E-G). In contrast to pneumococcal infection, ABT-737 24 
failed to enhance bacterial killing or to reconstitute apoptosis at the dose that induced 25 
 17 
apoptosis in transgenic BMDM after pneumococcal challenge (Figure E11B-C). ABT-1 
737 was used to reconstitute apoptosis since it does not alter uptake, in contrast to 2 
liposomes (3), in which altered phagocytosis can confound interpretation during high-3 
uptake phagocytosis, as seen with S. aureus. These findings highlight the importance of 4 
apoptosis-associated killing as a mechanism subverted by some pathogens. 5 
6 
 18 
Discussion:  1 
Development of a macrophage specific CD68.hMcl-1 transgenic mouse provided a 2 
unique means of examining the role and mechanism of macrophage apoptosis-associated 3 
bacterial killing in the lung. Use of this model identified a novel paradigm whereby 4 
macrophage apoptosis kills internalized bacteria that remain viable after initial 5 
phagolysosomal killing is exhausted. During apoptosis induction caspase-dependent 6 
mROS production combines with NO to achieve a second late-phase of bacterial killing. 7 
Inhibition of macrophage apoptosis by Mcl-1 increases susceptibility to bacterial 8 
infection but can be modulated pharmacologically to enhance pulmonary bacterial 9 
clearance. 10 
 11 
MacrophagesÕ avid phagocytic capacity ensures intracellular loading with ingested 12 
bacteria (37, 38). Phagocytosis activates an initial-phase of bacterial killing, consistent 13 
with observations describing temporal association of the NOX2 complex with neutrophil 14 
phagocytosis (24), but sustained phagocytosis overwhelms initial microbicidal 15 
responses. A late-phase microbicidal response, during the initial stages of apoptosis, 16 
clears remaining viable internalized bacteria. Macrophage apoptosis occurs during M. 17 
tuberculosis infection (39), but also with other pulmonary micro-organisms, such as 18 
pneumococci, unable to persist intracellularly, suggesting it limits intracellular 19 
persistence (11, 14).  20 
 21 
Our approach, using macrophage specific transgene expression (16), allowed selective 22 
modulation of the early stages of apoptosis via Mcl-1, with relative resistance to 23 
apoptosis, which regulates macrophage survival following pneumococcal infection (11). 24 
Mcl-1 is unique amongst anti-apoptotic Bcl-2 proteins because it is an early response 25 
 19 
gene with rapid induction and turnover (40). Mcl-1 transgene expression in myeloid 1 
cells prolongs macrophage survival but ensures sensitivity to physiological constraints 2 
on viability, and that cell numbers remain within the normal range (15).  3 
 4 
Emerging data in patients at risk of CAP show Mcl-1 upregulation in AM is associated 5 
with reduced bacterial killing  (12, 13). During HIV-1 infection gp120 inhibits Mcl-1 6 
ubiquitination and proteasomal degradation while in COPD transcriptional upregulation 7 
is associated with anti-oxidant responses during oxidative stress (12, 13) .  In our murine 8 
model over-expression of Mcl-1 using the human transgene converted low dose lung 9 
infections, which macrophages normally control (3), into established infections inducing 10 
neutrophilic inflammation, phenocopying the susceptibility of patient AM ex vivo. In 11 
comparison with S. pneumoniae and H. influenzae, S. aureus is less readily killed by 12 
differentiated macrophages (41) and internalized bacteria remain viable for several days 13 
(42). S. aureus containing-phagosomes fail to mature appropriately, decreasing 14 
cathepsin D activation required for Mcl-1 proteasomal degradation (14, 43).. We show S. 15 
aureus prevents apoptosis-associated killing, however unlike pneumococcal infection 16 
we could not reconstitute apoptosis-associated killing following S. aureus infection. A 17 
potential explanation for this finding could be that altered endosomal trafficking of S. 18 
aureus needs to be corrected (43), to allow induction of apoptosis and to allow co-19 
localization with mitochondria to mediate microbicidal killing (26). Thus HIV, COPD 20 
and S. aureus infection all inhibit bacterial killing by upregulating Mcl-1, similar to the 21 
over-expression of the human Mcl-1 transgene in our murine model. 22 
 23 
The relevance of animal models to human disease merits careful scrutiny. Murine 24 
pneumonia models confirm roles for the key innate cell populations contributing to 25 
pathogenesis in CAP and reprise the susceptibility of key single gene defects or 26 
 20 
polymorphisms identified in humans, despite some differences in specific innate 1 
responses (e.g. extent of reliance on NOS2 (inducible NO synthase) in macrophages, α-2 
defensin expression in neutrophils or activation patterns following specific Toll-like 3 
receptor ligands) (44). The C57Bl/6 strain has intermediate susceptibility to 4 
pneumococci (45) and inocula can be adapted to favour AM-dependent clearance or 5 
sequential requirement of T-cells and recruited neutrophils in this model (30). They also 6 
show evidence of AM apoptosis (3) and increased susceptibility to pneumococcal 7 
disease following Mcl-1 over-expression (11). A murine model allowed us to test the 8 
impact of genetic modulation of Mcl-1 in vivo in the context of early stage sub-clinical 9 
infection, something not possible in patients who present at the later stage of established 10 
disease. Impaired clearance of pneumococci in association with Mcl-1 upregulation in 11 
patient groups at increased risk of CAP suggests these finding are relevant to human 12 
disease. Moreover, we demonstrated key mechanistic requirements for caspase-13 
dependent mROS, combined with NO, in apoptosis-associated killing in human MDM, 14 
as well as increased bacterial clearance with BH3 mimetics. 15 
 16 
Apoptosis-associated bacterial killing requires mROS, a recently identified microbicidal 17 
(26). During apoptosis execution  caspase 3, inhibits mitochondrial electron transport 18 
complexes I and II (27), resulting in in generation of superoxide (46). SOD2 19 
upregulation during pneumococcal infection prevents necroptosis (47, 48)  ensuring 20 
mitochondrial permeabilization is limited in extent, a specific feature of apoptosis (11, 21 
14, 48, 49). However, antioxidant protection does not extend to the immediate 22 
environment of the phagolysosome, permitting microbial killing (26). Pneumococcal 23 
anti-oxidant systems protect against NADPH-dependent ROS generation in neutrophils 24 
(9). Our results, however, suggest that peak mROS and NO co-exist, consistent with the 25 
role of NO in the late microbicidal macrophage response (19, 25). Potential sources of 26 
 21 
NO include NOS2 but also NOS3 (endothelial NOS), which contributes to AM 1 
microbicidal responses to pneumococci (50) and mitochondria which generate NO 2 
through NOS-independent and NOS-dependent mechanisms (including the debated 3 
existence of an inner membrane-associated or matrix isoform) (51). Cross-reactivity of 4 
inhibitors between isoforms and residual controversies concerning NOS2 in humans 5 
means the source of NO requires further clarification. We propose a model where mROS 6 
and NO generation is temporally and spatially linked, and co-localizes with bacteria 7 
containing phagolysosomes as previously shown (19), allowing generation of reactive 8 
nitrogen species (RNS). We did not identify NO regulation by mROS, since mROS 9 
occurred downstream of Mcl-1-mediated apoptosis regulation, while NO production was 10 
upstream and unaltered by the Mcl-1 transgene. NO and RNS can, however, enhance 11 
mROS generation (51). We found no evidence that mROS role in killing was mediated 12 
by differential cytokine expression. While mROS can induce pro-inflammatory cytokine 13 
expression (28), during the early stages of bacterial-associated apoptosis induction 14 
protein translation is reduced, limiting this possibility (36).  15 
 16 
Since we demonstrate a critical role for apoptosis-associated killing in mediating 17 
bacterial clearance by macrophages, it follows that upregulation of Mcl-1 influences 18 
susceptibility to bacterial pneumonia. The use of a murine model in which we could 19 
alter Mcl-1 expression through transgene expression and deliver controlled infections 20 
and pharmacological interventions allowed us to confirm the role and mechanisms of 21 
this process to an extent not possible with our prior studies in patients (12, 13). Our data 22 
suggests that susceptibility to bacterial infection can be reversed through therapeutic 23 
targeting of the mitochondrial-microbicidal axis or modulation of Mcl-1. Several classes 24 
of therapeutics, including bisphosphonates and BH3 mimetics, target these pathways 25 
(20, 23). As proof of concept of this repurposing approach ABT737 has recently 26 
 22 
demonstrated utility in preventing intracellular replication of Legionella pneumophila in 1 
AM through induction of apoptosis (52). We also demonstrated Bcl-2 specific and pan-2 
Bcl-2 inhibitors enhanced pneumococcal clearance, with more significant results 3 
demonstrated for sabutoclax an agent that inhibits Mcl-1 (53). However, for some 4 
pathogens like S. aureus the strategy may need to be adapted to reverse altered 5 
endosomal trafficking (43). In view of the on-going therapeutic challenge of 6 
antimicrobial resistance, re-engaging this fundamental microbicidal mechanism in AM 7 
merits further evaluation. 8 
 9 
 10 
 11 
 12 
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Figure Legends 1 
 2 
Figure 1: Macrophages from CD68.hMcl-1 transgenic mice express hMcl-1 and 3 
have selective resistance to apoptosis.  4 
(A) Schematic representation of the transgene construct. Human Mcl-1 (hMcl-1) 5 
expression is driven in macrophages by 2.9 kb of the CD68 promoter and Intron 1 6 
(IVS-1). (B-D) Western blot analysis of human (h) and murine (m) Mcl-1 protein 7 
expression in (B) bone marrow-derived macrophages (BMDM), (C) alveolar, and (D) 8 
peritoneal macrophages, from CD68.hMcl-1 non-transgenic (non-Tg) or transgenic 9 
(Tg) mice. (E) Peripheral blood neutrophils and splenic CD19
+
 B-lymphocytes 10 
(CD19+) or CD3
+
 T-lymphocytes (CD3+) were isolated from non-Tg or Tg mice.  11 
Cells were lysed and probed by western blot for human (h) Mc-1 protein expression. 12 
Blots representative of three independent experiments. The +ve control is human 13 
monocyte-derived macrophage lysate. (F-G) BMDM from non-Tg or Tg mice were 14 
irradiated with UV radiation and assessed for (F) nuclear fragmentation at the indicated 15 
time-points, n=4, ***= p<0.001, 2-way ANOVA, or (G) caspase 3/7 activation 16 
measuring relative luminescence units (RLU) at 8h, n=4, *= p<0.05, 2-way ANOVA. 17 
Data are represented as mean ±SEM. (H) Alveolar (AM) macrophages from non-Tg or 18 
Tg mice were left untreated (negative), or UV treated. 8 h after UV exposure, apoptosis 19 
was assessed by nuclear fragmentation, n=4-5, ***= p<0.001 2-way ANOVA. Data are 20 
represented as mean ±SEM. See also Figure E1.  21 
 22 
                   Figure 2: Apoptosis-associated killing ensures intracellular bacterial clearance 23
when canonical phagolysosomal killing is exhausted. 24 
(A) Bone marrow-derived macrophages (BMDM) from CD68.hMcl-1 non-transgenic 25 
(non-Tg) or transgenic (Tg) mice were mock-infected (MI) or challenged with serotype 26 
2 S. pneumoniae (Spn) at a multiplicity of infection (MOI) of 10 and intracellular colony 27 
 28 
forming units (CFU) assessed 20 h after infection, n=18, **= p<0.01, unpaired StudentÕs 1 
t-test. (B) Non-Tg or Tg BMDM were challenged with Spn in the presence (+) or 2 
absence (-) of ABT-737. 20 h post-challenge cells were assessed for intracellular CFU, 3 
n=9, ***= p<0.001, 2-way ANOVA. (C) Non-Tg or Tg BMDM were challenged with 4 
Spn at MOI of 10 for 4 h and extracellular bacteria removed (Ôpulse-chaseÕ design). 5 
BMDM were lysed for initial assessment of CFU or incubated in vancomycin until the 6 
designated time point when CFU were also determined, n=4, **= p<0.01, 2-way 7 
ANOVA.  (D-E) BMDM were challenged with Spn at MOI of 10. At the designated 8 
time post-challenge, levels of apoptosis, (D), and the average number of cells per field 9 
(E), were measured, n=4, *= p<0.05, 2-way ANOVA. (F) Non-Tg or Tg BMDM were 10 
challenged with Spn at MOI of 10 for varying times before extracellular bacteria were 11 
killed and intracellular CFU estimated immediately or after a further 2 h incubation to 12 
measure intracellular killing capacity, n=4, **= p<0.01, 2-way ANOVA.  (G) Non-Tg 13 
or Tg BMDM were challenged with Spn at MOI of 10 for varying intervals before 14 
extracellular bacteria were killed and cultures split, and one group were ÔpulsedÕ with 15 
streptomycin resistant Spn (FP58) for 2 h, after which the intracellular CFU of FP58 16 
were estimated as a marker of recent ingestion, n=5. Data are represented as mean 17 
±SEM. See also Figures E2-3. 18 
 19 
 20 
Figure 3. Mcl-1 regulates caspase-induced late-phase mitochondrial ROS 21 
production. 22 
(A-B) Bone marrow-derived macrophages (BMDM) from CD68.hMcl-1 non-transgenic 23 
(non-Tg) or transgenic (Tg) mice were challenged with serotype 2 Streptococcus 24 
pneumoniae (Spn) at a multiplicity of infection (MOI) of 10 in the presence (+) or 25 
absence of the antioxidant Trolox, or an iNOS inhibitor (1400W). (A) Intracellular 26 
 29 
bacterial colony forming units (CFU) were estimated 16 h post-challenge, n=5, or (B) 1 
nuclear fragmentation was recorded 20 h post-challenge, n=6, **= p<0.01, 1-way or 2-2 
way ANOVA for analyses within or between groups respectively. (C) Non-Tg or Tg 3 
BMDM were mock-infected (MI) or challenged with Spn at MOI of 10. At the indicated 4 
times post-challenge cells were stained with MitoSOX and analysed by flow cytometry. 5 
n=3 *= p<0.05, Students t-test.  (D) Non-Tg or Tg BMDM were MI or challenged with 6 
Spn at MOI of 10. At the designated time points, cells were stained for mROS and 7 
caspase 3/7 activity by flow cytometry. Cells were selected by forward/side scatter (grey 8 
contour plots), before being designated as caspase negative or positive (green contour 9 
plots). MitoSox red staining was assessed for each caspase subpopulation and cell 10 
populations as a whole (histograms). Representative plots are shown, with collated data 11 
in the graph below, n=3 *= p<0.05, 2-way ANOVA. (E) Experiments in D were repeated 12 
in human MDM, n=4 *= p<0.05, 1-way ANOVA.  (F-G) Non-Tg or Tg BMDM (F) or 13 
human MDM (G) were challenged with Spn at MOI of 10, in the presence or absence 14 
(vehicle) of mitoTEMPO (mT), 1400W, or a combination of both (Combo). 16 h post-15 
challenge intracellular CFU were assessed, n=5 (for F) and n=8 (for G), *= p<0.05, **= 16 
p<0.01, repeated measures 1-way ANOVA (for F), or Friedman test (for G). (H-I) 17 
BMDM from non-Tg or Tg mice were MI or challenged with Spn at MOI of 10 in the 18 
presence (+) or absence (-) of mT. 20 h post-challenge cells were assessed by nuclear 19 
morphology (H), n=3, *= p<0.05, **= p<0.01, 2-way ANOVA, or (I) lysates were 20 
probed for human (h) and murine (m) Mcl-1 expression by western blot and densitometry 21 
performed on three independent experiments. Data are represented as mean ±SEM. See 22 
also Figures E4-7. 23 
 24 
 30 
Figure  4. Apoptosis-associated killing mediates bacterial clearance in vivo. 1 
(A-E) CD68.hMcl-1 non-transgenic (non-Tg) or transgenic (Tg) mice were challenged 2 
with the designated dose of serotype 1 Streptococcus pneumoniae (Spn). 24 h after 3 
instillation, bacterial colony forming units (CFU) in the lung homogenate (A) or blood 4 
(B), the number of polymorphonuclear leukocytes (PMN) (C), the number of alveolar 5 
macrophages (AM) (D), or the percentage of apoptotic AM (E) in the bronchoalveolar 6 
lavage (BAL) were measured, n=4-11 mice per group from three independent 7 
experiments, *= p<0.05 **= p<0.01, 2-way ANOVA. (F-H) Non-Tg and Tg mice were 8 
challenged with H. influenzae type b (Hib) at the designated dose. 24 h after instillation, 9 
CFU in the lung homogenate (F), PMN numbers in the BAL (G), and AM apoptosis (H), 10 
were measured, n=4-13 mice per group, from 2 independent experiments, ***= p<0.001, 11 
2-way ANOVA. (I-L) Non-Tg or Tg mice were challenged with the designated dose of 12 
Spn intra-peritoneally. 24 h after challenge, the bacterial CFU in the peritoneal lavage 13 
(PL) (I), n=7, or blood (J), were determined, n=7, and PMN numbers (K), n=7 and levels 14 
of peritoneal macrophage (PM) apoptosis (L), n=9, in the PL were assessed by 15 
microscopy. In all experiments, *= p<0.05, **= p<0.01, 2-way ANOVA. See also 16 
Figure E8. 17 
 18 
Figure 5: Apoptosis-associated killing can be reconstituted following challenge with 19 
Streptococcus pneumoniae 20 
(A) Bone marrow-derived macrophages (BMDM) from CD68.hMcl-1 non-transgenic 21 
(non-Tg) or transgenic (Tg) mice were challenged with liposomes containing PBS 22 
(LIPO-PBS) or clodronate (LIPO-CLOD).  At the designated time-point cells were fixed 23 
and analysed for nuclear fragmentation, n=3. (B) Wt or Tg BMDM were challenged 24 
with serotype 2 S. pneumoniae D39 (Spn) at a multiplicity of infection (MOI) of 10 in 25 
the presence of LIPO-PBS or LIPO-CLOD. 4 h post-challenge numbers of intracellular 26 
 31 
bacterial colony forming units (CFU) were assessed, n=3. (C-D) Non-Tg or Tg mice 1 
were infected with serotype 1 S. pneumoniae (Spn) in the presence of LIPO-PBS or 2 
LIPO-CLOD. Alveolar macrophage (AM) numbers in bronchoalveolar lavage (BAL) 3 
(C), and AM apoptosis in BAL (D) were measured by microscopy 24 h post-challenge, 4 
both n=4, *= p<0.05, 2-way ANOVA. (E-G) Non-Tg and Tg mice were challenged with 5 
10
5
 serotype 1 Spn and liposome-encapsulated PBS (LIPO-PBS) or clodronate (LIPO-6 
CLOD). 24 h after challenge, CFU in the lung (E) and blood (F), and total 7 
polymorphonuclear leukocyte (PMN) numbers in the BAL (G) were measured, n= 6-13 8 
mice per group from 3 independent experiments. (H-I) Tg or non-Tg were instilled 9 
intranasally with 10
5
 colony forming units of serotype 2 S. pneumoniae then 10 
immediately treated with ABT-263 or sabutoclax. 24 h after challenge, CFU in the lung 11 
(H) and blood (I) were measured (median + interquartile range), n= 8-10, *= p<0.05, 12 
unpaired Students t-test, or 2-way ANOVA, for analyses within or between groups 13 
respectively. See also Figure E9-10. 14 
 15 
Figure 6: Staphylococcus aureus infection does not trigger apoptosis-associated 16 
killing.  17 
(A) Bone marrow-derived macrophages (BMDM) from CD68.hMcl-1 non-18 
transgenic (non-Tg) or transgenic (Tg) mice were challenged with S. aureus (Sa) at a 19 
multiplicity of infection (MOI) of 5.  BMDM were lysed at varying time points during 20 
a Ôpulse-chaseÕ to allow detection of intracellular bacterial colony forming units (CFU), 21 
n=3. (B) BMDM apoptosis, in the same experiments, n=3.  (C) BMDM were lysed for 22 
initial assessment of CFU or incubated in lysostaphin for 2 h, before CFU estimation to 23 
assess bacterial killing between the indicated time-points, n=3. (D) BMDM were 24 
challenged with Sa at MOI of 5 for varying time periods, extracellular bacteria killed 25 
and BMDM incubated with kanamycin and kanamycin resistant Sa, before extracellular 26 
 32 
bacteria were killed with lysostaphin and intracellular CFU measured at the designated 1 
time-points. The graph shows intracellular CFU, cultured in the presence of kanamycin 2 
to measure kanamycin resistant (recently ingested) bacteria over each time increment, 3 
n=3. (E-G) Non-Tg or Tg mice were challenged with Sa at the designated dose. 24 h 4 
post-challenge, bacterial CFU in the lung homogenate (E), PMN numbers in the 5 
bronchoalveolar lavage (BAL) (F) and alveolar macrophage (AM) apoptosis (G), were 6 
measured, n=4-9 mice per group, from three independent experiments. See also Figure 7 
E11. 8 
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